中国年龄靶向结核病疫苗接种及其对疫苗研发的启示:一项建模研究
该建模研究基于中国年龄分层的人口学和流行病学数据校准结核分枝杆菌传播模型,评估针对青少年或老年人的新结核疫苗在不同疫苗特性下的潜在影响。向老年人接种疫苗的人群水平影响更高、每避免一例病例或死亡所需接种人数更少,且感染后疫苗效果优于感染前疫苗。
要点
- 老年人接种疫苗的人群水平影响高于青少年接种,且每避免一例病例或死亡的NNV更低。
- 感染后疫苗在老年人中提供的发病率和死亡率降低幅度大于感染前疫苗。
核心结论
- 针对青少年的结核疫苗在老龄化、再激活驱动的疫情中影响有限,向老年人提供有效的感染后疫苗对最大化人群水平影响至关重要。
研究设计与样本
- 基于中国年龄分层人口学和流行病学数据校准的结核分枝杆菌传播模型,评估不同疫苗接种情景。
- 疫苗实施情景包括目标年龄(青少年15-19岁或老年人60-64岁)和覆盖率(30%或70%)。
- 疫苗特性包括效力(40%、60%或80%)、保护持续时间(10年或20年)和所需宿主感染状态。
主要发现
- 老年人接种时,感染后疫苗比感染前疫苗提供更大的死亡率和发病率降低幅度。
临床怎么用
- 在老龄化、再激活驱动的结核病疫情中,应优先考虑向老年人提供感染后疫苗,并将老年人纳入结核疫苗临床研发和实施规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis is the leading single-pathogen cause of death worldwide, and China has the third largest number of cases worldwide. New tools, such as new vaccines, are needed to meet WHO tuberculosis goals. Tuberculosis vaccine development strategies mostly target infants or adolescents, but given China's ageing epidemic, vaccinating older people might be important. We modelled the potential impact of new tuberculosis vaccines in China targeting adolescents (15-19 years) or older adults (60-64 years) with varying vaccine characteristics to inform strategic vaccine development. METHODS: A Mycobacterium tuberculosis transmission model was calibrated to age-stratified demographic and epidemiological data from China. Varying scenarios of vaccine implementation (age targeting [adolescents or older adults] and coverage [30% or 70%]) and characteristics (efficacy [40%, 60%, or 80%], duration of protection [10 years or 20 years], and host infection status required for efficacy [pre-infection, post-infection in latency, post-infection in latency or recovered, or pre-infection and post-infection]) were assessed. Primary outcomes were tuberculosis incidence and mortality rate reduction in 2050 in each vaccine scenario compared with the baseline (no new vaccine) scenario and cumulative number needed to vaccinate (NNV) per case or death averted, 2025-50. FINDINGS: By 2050, results suggest that 74·5% (uncertainty interval [UI] 70·2-78·6) of incident tuberculosis cases in China would occur in people aged 65 years or older, and 75·1% (66·8-80·7) of all cases would be due to reactivation, rather than new infection. All vaccine profiles delivered to older adults had higher population-level impact (reduction of incidence and mortality rates) and lower NNV per case and per death averted than if delivered to adolescents. For an intermediate vaccine scenario of 60% efficacy, 10-year protection, and 70% coverage, the reduction of tuberculosis incidence rates with older adult vaccination was 1·9 times (UI 1·5-2·6) to 157·5 times (119·3-225·6) greater than with adolescent vaccination, and the NNV was 0·011 times (0·008-0·014) to 0·796 times (0·632-0·970) lower. Furthermore, with older adult vaccination, post-infection vaccines provided substantially greater mortality and incidence rate reductions than pre-infection vaccines. INTERPRETATION: Adolescent-targeted tuberculosis vaccines, the focus of many development plans, would have only a small impact in ageing, reactivation-driven epidemics such as those in China. Instead, an efficacious post-infection vaccine delivered to older adults will be crucial to maximise population-level impact in this setting and would provide an important contribution towards achieving WHO goals. Older adults should be included in tuberculosis vaccine clinical development and implementation planning. FUNDING: Aeras and UK MRC.
引用
- Harris RC, Sumner T, Knight GM, et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 2019. PMID: 30630775. doi:10.1016/S2214-109X(18)30452-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。